BioMarin

YTD

ALL

Trade BioMarin 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMRN

BioMarin Pharmaceutical, Inc. is a global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. The company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline.

CEO

Alexander Hardy

CEOAlexander Hardy

Employees

3,221

Employees3,221

Headquarters

San Rafael, California

HeadquartersSan Rafael, California

Founded

1997

Founded1997

Employees

3,221

Employees3,221

BMRN Key Statistics

Market cap

10.88B

Market cap10.88B

Price-Earnings ratio

-551.98

Price-Earnings ratio-551.98

Dividend yield

—

Dividend yield—

Average volume

2.70M

Average volume2.70M

High today

$58.00

High today$58.00

Low today

$55.97

Low today$55.97

Open price

$57.39

Open price$57.39

Volume

1.28M

Volume1.28M

52 Week high

$70.98

52 Week high$70.98

52 Week low

$49.26

52 Week low$49.26

Stock Snapshot

The current BioMarin(BMRN) stock price is $56.15, with a market capitalization of 10.88B. The stock trades at a price-to-earnings (P/E) ratio of -551.98.

As of 2026-11-05, BioMarin(BMRN) stock has fluctuated between $55.97 and $58.00. The current price stands at $56.15, placing the stock +0.3% above today's low and -3.2% off the high.

The BioMarin(BMRN)'s current trading volume is 1.28M, compared to an average daily volume of 2.7M.

During the past year, BioMarin(BMRN) stock moved between $49.26 at its lowest and $70.98 at its peak.

BMRN News

Simply Wall St 1d

BioMarin Pharmaceutical Stock Dropped, What Is Behind Its Latest Update?

BioMarin Pharmaceutical (BMRN) just cleared the US$1b mark in Q3 2026 revenue yet trimmed its full year outlook as Voxzogo order timing and integration costs we...

TipRanks 2d

BioMarin’s Resilient Growth Outlook Supports Buy Rating Despite Price-Target Cut to $89

BioMarin Pharmaceutical, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yun Zhong from Wedbush maintained a Buy rating on...

Simply Wall St 3d

BioMarin Stock May Still Be A Bargain On Fabry Licensing Deal

has added fresh deals and pipeline assets while its stock has declined 31.2% over the past five years, which puts a sharper spotlight on whether its current mar...

Analyst ratings

77%

of 31 ratings

Buy

77.4%

Hold

22.6%

Sell

More BMRN News

TipRanks 3d

BioMarin’s Timing-Related Setback Masks Long-Term Growth Potential, Supporting a Buy Rating with 32.3% Upside

BioMarin Pharmaceutical, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Eric Joseph from Citi reiterated a Buy rating...

Simply Wall St 6d

How Investors Are Reacting To BioMarin Pharmaceutical Fabry Disease Licensing Deal

On 29 October 2026, GC Biopharma and Hanmi Pharm announced an exclusive worldwide license agreement granting BioMarin Pharmaceutical rights outside Korea to HM1...

People also own

Based on the portfolios of people who own BMRN. This list is generated using Robinhood data, and it’s not a recommendation.

Boston Scientific

Alnylam Pharmaceuticals

KKR & Co

NRG Energy

Sprouts Farmers Market

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.